A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma

Inclusion Criteria: Signed written informed consent In the Phase I portion, Asian subjects that are > or = to 18 years of age In the Phase II portion, any subjects that are > or = to 18 years of age Non-resectable locally advanced, recurrent, or metastatic hepatocellular carcinoma (HCC) that is either histologically proven or a radiologically documented liver mass with: (alpha-fetoprotein [AFP] > 4,000 ng/mL, hepatitis B surface antigen positive or alpha-fetoprotein [AFP] > 400 ng/mL, hepatitis B surface antigen negative) Radiologically documented measurable disease Adequate performance status and organ function, as evidenced by hematologic and biochemical blood testing Willing to not receive fluoropyrimidine containing chemotherapy for 8 weeks after the last dose of ADH300004 in this study Exclusion Criteria: Chemotherapy, radiotherapy, or any other investigational drug within 28 days prior to study entry No more than 1 previous treatment with systemic chemotherapy (chemotherapy administered as part of a chemo-embolization procedure is not considered systemic chemotherapy) Portal hypertension with bleeding esophageal or gastric varices within the past 3 months Ascites that is refractory to conservative management Inability to take oral medication Active peptic ulcer disease Known hypersensitivity to 5-FU or ADH300004 History of primary brain tumors or brain metastases Previous or concurrent malignancy at another site within the last 5 years Stroke, major surgery, or other major tissue injury within 30 days before study entry